Molecular epidemiology of hormone-metabolic loci in prostate cancer

Epidemiologic Reviews

Volumn 23, Issue 1, 2001, Pages 24-29

  Makridakis, Nick M ^a   Reichardt, Juergen K V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE;

ANDROGEN BLOOD LEVEL; CANCER RISK; CANCER SUSCEPTIBILITY; HORMONE METABOLISM; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; UNITED STATES;

EID: 0034801570     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a000791     Document Type: Review

References (60)

1. Cancer statistics, 2000
2. Vitamin D and prostate cancer risk
3. 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males
4. Studies on prostate cancer
5. The role of steroid hormones in prostate carcinogenesis
6. The development of prostate adenocarcinoma in Nb rats following prolonged sex hormone administration
7. Endocrinology of the prostate
8. Genes involved in androgen biosynthesis and the male phenotype
9. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
10. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
11. Promoter specific activation of RNA polymerase II transcription by SpI
12. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1
13. Prostate cancer associated with CYP17 genotype
14. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression
15. Steroid 5α-reductase 2 deficiency
16. Molecular genetics of steroid 5α-reductase 2 deficiency
17. Steroid 5α-reductase: Two genes/two enzymes
18. The identification of 5α-reductase-2 and 17β-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred
19. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk
20. A prevalent missence substitution that modulates activity of prostatic steroid 5α-reductase
21. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
22. A polymorphism of the 5α-reductase gene and its association with prostate cancer: A case-control analysis
23. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
24. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
25. Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II
26. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5α-reductase during prostate cancer progression
27. Enzymes of androgen formation and degradation in the human prostate
28. Structure and tissue-specific expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissue
29. Assignment of the human 3β-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1
30. Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene
31. 4 isomerase (3β-HSD) gene: Adrenal and gonadal specificity
32. Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency
33. Functional characterization of the novel L108W and P186L mutations detected in the type II 3β-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia
34. Dinucleotide repeat polymorphisms in the HSD3B2 gene
35. Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk
36. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
37. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
38. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
39. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
40. n CAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
41. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
42. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
43. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
44. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility
45. The androgen receptor gene GGN microsatellite and prostate cancer risk
46. Androgen receptor mutations in prostate cancer
47. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
48. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
49. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
50. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3
51. Molecular genetics and pathophysiology of 17β-hydroxysteroid dehydrogenase 3 deficiency
52. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer
53. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions
54. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis
55. Aromatase in hyperplasia and carcinoma of the human prostate
56. Aromatase and breast cancer susceptibility
57. Genetic variants of CYP19 (aromatase) and breast cancer risk
58. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases
59. Genetics of prostate cancer: Too many loci, too few genes